Abstract
In 4 patients with primary pulmonary hypertension, there was a -24% +/- 20% decrease in pulmonary vascular resistance, a significant increase of cardiac index by +27 +/- 14% in all 4 patients; a -15 +/- 12% decrease in pulmonary artery pressure in 3 patients; and in 3 patients with 12% secondary pulmonary hypertension, there was a -24 +/- 14% decrease in pulmonary vascular resistance. Beraprost appears to be effective as a new pulmonary vasodilative agent.
MeSH terms
-
Adult
-
Child
-
Epoprostenol / analogs & derivatives*
-
Epoprostenol / pharmacology
-
Epoprostenol / therapeutic use
-
Female
-
Hemodynamics / drug effects*
-
Humans
-
Hypertension, Pulmonary / drug therapy
-
Hypertension, Pulmonary / physiopathology*
-
Infant
-
Male
-
Middle Aged
-
Platelet Aggregation Inhibitors / pharmacology*
-
Platelet Aggregation Inhibitors / therapeutic use
-
Treatment Outcome
-
Vasodilator Agents / pharmacology*
-
Vasodilator Agents / therapeutic use
Substances
-
Platelet Aggregation Inhibitors
-
Vasodilator Agents
-
beraprost
-
Epoprostenol